Immunohistochemical Analysis of ALK Fusion-Positive Lung Cancers: Correlation with FISH, Molecular Findings and Morphology

被引：0
|
作者：
Saab, S. T.
Lovly, C.
Hollis, C. J.
Ashwini, Y.
Ji, H.
Pao, W.
Gonzalez, A.
机构：
[1] Vanderbilt Univ, Nashville, TN USA
[2] Chinese Acad Sci, Shanghai, Peoples R China
来源：
MODERN PATHOLOGY | 2011年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1799
引用
收藏
页码：423A / 423A
页数：1
相关论文
共 50 条
  • [31] Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review
    Han, Dan
    Zhao, Kewei
    Yang, Qin
    Zhang, Liling
    Fei, Shihong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Correlation of Cytomorphology and Molecular Findings in EGFR plus . KRAS plus , and ALK plus Lung Carcinomas
    Li, Zaibo
    Dacic, Sanja
    Pantanowitz, Liron
    Khalbuss, Walict E.
    Nikiforova, Marina N.
    Monaco, Sara E.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (03) : 420 - 428
  • [33] Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib
    Choudhury, Noura J.
    Woo, Hyung Jun
    Chen, Monica
    Shah, Ronak
    Donoghue, Mark
    Berger, Michael
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2024, 8
  • [34] NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.
    Duruisseaux, Michael
    Liu, Stephen V.
    Han, Ji-Youn
    Gounant, Valerie
    Shih, Jin-Yuan
    Schram, Alison M.
    Schrock, Alexa Betzig
    Ali, Siraj Mahamed
    Magne, Fanny
    Monnet, Isabelle
    Moro-Sibilot, Denis
    Blum, Torsten-Gerriet
    Patil, Tejas
    Doebele, Robert Charles
    Camidge, D. Ross
    Muscarella, Lucia Anna
    Cadranel, Jacques
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances
    Cabillic, Florian
    Gros, Audrey
    Dugay, Frederic
    Begueret, Hugues
    Mesturoux, Laura
    Chiforeanu, Dan Cristian
    Dufrenot, Leila
    Jauffret, Vincent
    Dachary, Dominique
    Corre, Romain
    Lespagnol, Alexandra
    Soler, Gwendoline
    Dagher, Julien
    Catros, Veronique
    Le Calve, Michele
    Merlio, Jean-Philippe
    Belaud-Rotureau, Marc-Antoine
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) : 295 - 306
  • [36] Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
    Ali, Faraat
    Neha, Kumari
    Chauhan, Garima
    ARCHIVES OF PHARMACAL RESEARCH, 2022, 45 (05) : 309 - 327
  • [37] Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib
    Choudhury, Noura J.
    Woo, Hyung Jun
    Chen, Monica
    Shah, Ronak
    Donoghue, Mark
    Berger, Michael
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2024, 8
  • [38] Central nervous system (CNS) outcomes and progression patterns in patients with RET fusion-positive lung cancers treated with selpercatinib.
    Murciano-Goroff, Yonina R.
    Falcon, Christina J.
    Lin, Sabrina T.
    Dhawan, Aradhika
    Grimaldi, Grace
    Liu, Dazhi
    Wilhelm, Clare
    Thomas, Reeja
    Iasonos, Alexia
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
    Subbiah, Vivek
    Gainor, Justin F.
    Oxnard, Geoffrey R.
    Tan, Daniel S. W.
    Owen, Dwight H.
    Cho, Byoung Chul
    Loong, Herbert H.
    Mccoach, Caroline E.
    Weiss, Jared
    Kim, Yu Jung
    Bazhenova, Lyudmila
    Park, Keunchil
    Daga, Haruko
    Besse, Benjamin
    Gautschi, Oliver
    Rolfo, Christian
    Zhu, Edward Y.
    Kherani, Jennifer F.
    Huang, Xin
    Kang, Suhyun
    Drilon, Alexander
    CLINICAL CANCER RESEARCH, 2021, 27 (15) : 4160 - 4167
  • [40] Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
    Faraat Ali
    Kumari Neha
    Garima Chauhan
    Archives of Pharmacal Research, 2022, 45 (5) : 309 - 327
12345